Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC., Parsnippany, NJ 07 Recall

Ongoing
Drugs
Class II — Moderate

Recall Date

Jul 29, 2026

Company

Ascend Laboratories, LLC

Source

FDA

Units

6,192 bottles

Reason: Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Class II: Use of the product may cause temporary or medically reversible health problems.

Official FDA recall notice

Information is from official FDA notices. Do not stop taking any medication without consulting your doctor or pharmacist first — the risks of stopping may be greater than the risk from the recalled product.

Recall Details

Description

Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Reason for Recall

Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Product: Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC., Parsnippany, NJ 07
Official Recall ID: FDA-DRUG-D-0712-2026
Units affected: 6,192 bottles

What Should I Do?

Check your lot number. Don't stop taking a prescribed medication without talking to your pharmacist or doctor. Contact the pharmacy where you got it about a replacement.

Quantity: 6,192 bottles

Remediation GuideAction Required

5-step guide to help you action required this recalled product. Click Start Remediation to track your progress.

1
Confirm Your Product Is Affected
2
Read the Full Recall Notice
3
Stop Using the Product if in Doubt

+2 more steps…

View Official Recall Notice (FDA)

Last updated August 4, 2026

More recalls from Ascend Laboratories, LLC

Similar recalls

Injured by a recalled product?

Our legal partners offer free consultations for recall victims.

Get Free Legal Help →Sponsored

Stay Informed

Weekly recall digest — free, no spam.